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Model Assessment: 
•  Accuracy: Validation against historical data shows good predictability for 
aggregate forecasts, but weaker predictability for finer metrics; 
questionable historical data represents greatest source of error 
•  Usability: Iterative design and frequent user feedback led to extremely user-
friendly design;  Fast simulation time (e.g., 1-3 minutes) allows real-time 
scenario analysis 
•  Leadership buy-in: Strong response from research management; will present 
new capability to broader NIBR leadership in February 2010; trained an 
internal technical expert and champion to allow future model growth. 
Pharmaceutical R&D involves considerable uncertainty, including: 
•  High attrition – a large number of projects must be undertaken to yield a 
relatively small number of compounds that enter clinical development; the 
likelihood of commercial success for any single discovery project is 
extremely low.  
•  High project-to-project variability in time and resources required to reach 
subsequent phases of development  
•  Long concept-to-commercialization time (~8-12 years) 
Senior leaders must make decisions today about pipeline size and balance, the 
impact of which will not be observable for many years. 
NIBR’s Portfolio Management Group (PMG) aims to create tools that aid senior 
management in understanding pipeline status and progress. The PMG cites 
forward projection as a desired capability not currently achieved in a 
systematic, aggregated fashion. Key questions include: 
•  Given the current pipeline, how many successful proof-of-concept (POC) 
studies can we expect in x-years? To achieve a desired number of POCs in x-
years, what should our pipeline look like?  
•  How can various pipeline levers affect pipeline productivity? 
Primary goal: To create a forward-looking pipeline model that 
•  Accounts for system complexity and uncertainty 
•  Incorporates historical performance data  
•  Is easy to use to support real-time managerial decisions 
Expected benefits: Bridging strategy and execution by facilitating 
•  Scenario Analysis 
•  Resource Planning 
•  Portfolio Gap Identification and Resolution 
Novartis AG is a global leader in pharmaceuticals, vaccines, generics, and 
consumer health products. Its mission is to discover, develop and successfully 
market innovative products to prevent and cure diseases, to ease suffering and 
to enhance the quality of life. 
•  Headquartered in Basel, Switzerland 
•  100,000 associates in 140 countries 
Novartis Institutes for Biomedical Research (NIBR) is the global research 
organization of Novartis. Its research approach prioritizes patient need and 
disease understanding, and emphasizes proof-of-concept trials – small-scale 
studies used to get an early read on the safety and efficacy of drug candidates. 
•  Headquartered in Cambridge, MA 
•  2008 R&D investment = $7.2B, or 17.4% of sales 
Understanding the Real-World: The Drug Pipeline 
Modeling the Real-World: Scoping and Data Collection 
Input Parameters: 
•  Phase Durations 








Planning Model Development: Iterative, Incremental Design 
Output data: 
•  Probabilistic forecasts 
of pipeline status 
Capabilities: 
•  Scenario Analysis 
•  Resource Planning 
•  Portfolio Gap ID 
Source:  Novartis Company Website; www.novartis.com 
Baseline 
model 
•  Mock data 
•  Project transitioning (durations, transition rates) 
•  Monte Carlo Simulation 
Iteration 1 
•  Historical data 
•  Multiple project types (e.g., small-molecule versus biologics) 
•  “Expansion points” (e.g., backup projects) 
Iteration 2 
•  More historical data 
•  Leadership reports 
•  UI improvements 
User Interface 
User input with 
probabilistic assumptions 
Modeling Tools: 
•  MS Excel – User interface and data input 
•  Visual Basic for Applications – Data handling 
•  Crystal Ball – Monte Carlo simulation 
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Dynamics Model output #1 
Near-term portfolio levers: 
•  Current projects -> should we in-license?  
•  Expansion points -> should we launch more 
backup programs?  
Long-term portfolio levers: 
•  Incoming projects -> should we increase 
resources at specific R&D phases? 
•  Expansion points -> should we encourage 
specific types/balance of projects? 
“The model output suggests near-term growth in 
portfolio size, but the expected inflow of new 
projects cannot sustain the peak size achieved 
next year.”  
*Note: Shown data is for  demonstration purposes  and not representative of Novartis’ actual research portfolio. 
“The model output shows a portfolio gap. The 
portfolio size will fall rapidly next year, but the high 
expected inflow of new projects will build it back 
up over the next 5 years.”  
Model output #2 
Model output #3 
“The model output shows that in 3 years, we will 
achieve at least 6 positive proof-of-concept 
studies with 59% certainty.”  
